Brief: Sanofi's COVID-19 Vaccine Nuvaxovid Authorised In Canada
09/04/2026 15:02
April 9 (Reuters) - Sanofi SA SASY.PA: SANOFI BECOMES MARKET AUTHORIZATION HOLDER FOR NUVAXOVID® IN CANADA, EXPANDING COVID-19 VACCINE CHOICES FOR CANADIANS TO MAKE NUVAXOVID AVAILABLE IN CANADA FOR FALL 2026-2027 SEASON PROVINCIAL, TERRITORIAL AVAILABILITY TO BE CONFIRMED PENDING ONGOING DISCUSSIONS, ASSESSMENTS Source text: ID:nCNWx1628a Further company coverage: SASY.PA (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Sanofi SA
See all newsFDA approves expanded use of Sanofi's type 1 diabetes drug (updated)
Brief: FDA Approves Tzield For Pediatric Stage 3 Type I Diabetes
FDA approves Sanofi's drug for stage 3 type 1 diabetes in children
European shares steady as investors weigh US-Iran flare-up (updated)
European shares steady as investors cling to Mideast peace hopes